NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $21,570 | -64.6% | 37,500 | +95.4% | 0.00% | -50.0% |
| Q3 2022 | $61,000 | -86.0% | 19,191 | -76.3% | 0.00% | -88.2% |
| Q1 2022 | $436,000 | +14.1% | 80,847 | +185.6% | 0.02% | +13.3% |
| Q4 2021 | $382,000 | -73.7% | 28,303 | -65.0% | 0.02% | -71.7% |
| Q3 2021 | $1,451,000 | -13.4% | 80,804 | -17.2% | 0.05% | +39.5% |
| Q2 2021 | $1,675,000 | +203.4% | 97,636 | +253.8% | 0.04% | +123.5% |
| Q1 2021 | $552,000 | -69.8% | 27,596 | -74.4% | 0.02% | -72.1% |
| Q4 2020 | $1,829,000 | – | 107,600 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |